CoChat

Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

Open access

The DOI matches its Crossref record; 22 of the 25 references it cites were found in a registry or an index.

Abstract

Context: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose reduction. Objective: Assess tildacerfont safety and efficacy. Design and Setting: Two Phase 2 open-label studies. Patients: Adults with 21OHD. Intervention: Oral tildacerfont 200 to 1000 mg once daily (QD) (n = 10) or 100 to 200 mg twice daily (n = 9 and 7) for 2 weeks (Study 1), and 400 mg QD (n = 11) for 12 weeks (Study 2). Main Outcome Measure: Efficacy was evaluated by changes from baseline at 8 am in adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) according to baseline A4 ≤ 2× upper limit of normal (ULN) or A4 > 2× ULN. Safety was evaluated using adverse events (AEs) and laboratory assessments. Results: In Study 1, evaluable participants with baseline A4 > 2× ULN (n = 11; 19-67 years, 55% female) had reductions from baseline in ACTH (−59.4% to −28.4%), 17-OHP (−38.3% to 0.3%), and A4 (−24.2% to −18.1%), with no clear dose response. In Study 2, participants with baseline A4 > 2× ULN (n = 5; 26-63 years, 40% female) had ~80% maximum mean reductions in biomarker levels. ACTH and A4 were normalized for 60% and 40%, respectively. In both studies, participants with baseline A4 ≤ 2× ULN maintained biomarker levels. AEs (in 53.6% of patients overall) included headache (7.1%) and upper respiratory tract infection (7.1%). Conclusions: For patients with 21OHD, up to 12 weeks of oral tildacerfont reduced or maintained key hormone biomarkers toward normal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgab438

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study designs and patient flow. (A) Study 201 design. Study 201 was a Phase 2a, multicenter, open-label, multiple-dose, dose-escalation study. Participants in Cohort A received oral tildacerfont 200 mg once daily (QD) for 2 weeks, escalating to 600 mg QD for 2 weeks, and then 1000 mg QD for 2 weeks with no washout between doses. Participants in Cohorts B and C received tildacerfont 200 mg twice daily (BID) or 100 mg BID, respectively, for 2 weeks with dosing at 10 am and 10 pm. Serial blood samples for pharmacodynamic profiles and pharmacokinetic analyses were collected during overnight visits at baseline (days −1/1) and week 2 (days 14/15) of each treatment period. The study enrolled 24 participants overall, but 2 participants contributed data to 2 cohorts. (B) Study 202 design. Study 202 was a 12-week, Phase 2, multicenter, open-label study evaluating oral tildacerfont 400 mg QD. Trial visits were conducted in the morning, approximately 8 am, prior to consumption of a morning GC dose at baseline (day 1); weeks 2, 4, 6, 8, 10, and 12; and 30 days after the last dose. (C) Patient flow. Poor disease control was defined as androstenedione (A4) > 2× ULN at baseline. Good disease control was defined as A4 ≤ 2× ULN at baseline. *In Study 201, 1 individual on dexamethasone participated in both Cohorts A and B. †In Study 201, 1 individual with poor disease control at baseline participated in both Cohorts A and C. ‡One individual who participated in both studies had liver enzyme elevations during Study 201 and then discontinued Study 202 after experiencing rash without pruritus and smaller increases in liver enzymes.
Figure 1. Study designs and patient flow. (A) Study 201 design. Study 201 was a Phase 2a, multicenter, open-label, multiple-dose, dose-escalation study. Participants in Cohort A received oral tildacerfont 200 mg once daily (QD) for 2 weeks, escalating to 600 mg QD for 2 weeks, and then 1000 mg QD for 2 weeks with no washout between doses. Participants in Cohorts B and C received tildacerfont 200 mg twice daily (BID) or 100 mg BID, respectively, for 2 weeks with dosing at 10 am and 10 pm. Serial blood samples for pharmacodynamic profiles and pharmacokinetic analyses were collected during overnight visits at baseline (days −1/1) and week 2 (days 14/15) of each treatment period. The study enrolled 24 participants overall, but 2 participants contributed data to 2 cohorts. (B) Study 202 design. Study 202 was a 12-week, Phase 2, multicenter, open-label study evaluating oral tildacerfont 400 mg QD. Trial visits were conducted in the morning, approximately 8 am, prior to consumption of a morning GC dose at baseline (day 1); weeks 2, 4, 6, 8, 10, and 12; and 30 days after the last dose. (C) Patient flow. Poor disease control was defined as androstenedione (A4) > 2× ULN at baseline. Good disease control was defined as A4 ≤ 2× ULN at baseline. *In Study 201, 1 individual on dexamethasone participated in both Cohorts A and B. †In Study 201, 1 individual with poor disease control at baseline participated in both Cohorts A and C. ‡One individual who participated in both studies had liver enzyme elevations during Study 201 and then discontinued Study 202 after experiencing rash without pruritus and smaller increases in liver enzymes.CC BY-NC-ND · PubMed Central
Figure 2. Tildacerfont pharmacokinetics profiles (Study 201). In Cohort A [200, 600, or 1000 mg once daily (QD)], participants received tildacerfont at 10 pm. One participant in Cohort B and 1 participant in Cohort A at 1000 mg were discontinued prior to day 14 pharmacokinetic assessments. Participants who received twice daily (BID) dosing of tildacerfont received the dose at 10 am and 10 pm each day.
Figure 2. Tildacerfont pharmacokinetics profiles (Study 201). In Cohort A [200, 600, or 1000 mg once daily (QD)], participants received tildacerfont at 10 pm. One participant in Cohort B and 1 participant in Cohort A at 1000 mg were discontinued prior to day 14 pharmacokinetic assessments. Participants who received twice daily (BID) dosing of tildacerfont received the dose at 10 am and 10 pm each day.CC BY-NC-ND · PubMed Central
Figure 3. Representative drug-drug interaction between tildacerfont and dexamethasone (n = 1; Study 201). Representative participants demonstrating increase in dexamethasone exposures with administration of tildacerfont. (A) Tildacerfont dose-dependent increase in dexamethasone exposures is observed in the participant in Cohort A receiving doses from 200 to 1000 mg once daily (QD) with dexamethasone dosing prior to time 0. (B) Increase in dexamethasone exposure with tildacerfont 200 mg twice daily (BID) over 24 h with administration of dexamethasone at approximately 10 pm (12 h post am dose).
Figure 3. Representative drug-drug interaction between tildacerfont and dexamethasone (n = 1; Study 201). Representative participants demonstrating increase in dexamethasone exposures with administration of tildacerfont. (A) Tildacerfont dose-dependent increase in dexamethasone exposures is observed in the participant in Cohort A receiving doses from 200 to 1000 mg once daily (QD) with dexamethasone dosing prior to time 0. (B) Increase in dexamethasone exposure with tildacerfont 200 mg twice daily (BID) over 24 h with administration of dexamethasone at approximately 10 pm (12 h post am dose).CC BY-NC-ND · PubMed Central
Figure 4. Overnight serum adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) levels at baseline and after 2 weeks of tildacerfont (Study 201). No participants at 200 mg twice daily (BID) qualified as having poor disease control. Participants with missing data (either baseline or 8 am) are not included. Participants with poor disease control had baseline ACTH and A4 levels that were more than twice the upper limit of normal. Participants with good disease control had baseline ACTH and A4 levels that were less than twice the upper limit of normal. Abbreviation: QD, once daily.
Figure 4. Overnight serum adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) levels at baseline and after 2 weeks of tildacerfont (Study 201). No participants at 200 mg twice daily (BID) qualified as having poor disease control. Participants with missing data (either baseline or 8 am) are not included. Participants with poor disease control had baseline ACTH and A4 levels that were more than twice the upper limit of normal. Participants with good disease control had baseline ACTH and A4 levels that were less than twice the upper limit of normal. Abbreviation: QD, once daily.CC BY-NC-ND · PubMed Central
Figure 5. Changes from baseline in adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) levels at 8 am during 12 weeks of tildacerfont treatment by baseline disease control status (Study 202). Participants were required to be on a stable regimen of glucocorticoid replacement for a minimum of 30 days before baseline that was expected to remain stable throughout the study. Assessments were taken at approximately 8 am prior to morning glucocorticoid dose. Geometric means are presented with percentage reduction derived from the geometric mean ratios. Axes are different between poor and good disease control to enable presentation of good disease control participants with mean values below the target levels. Abbreviation: QD, once daily.
Figure 5. Changes from baseline in adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP), and androstenedione (A4) levels at 8 am during 12 weeks of tildacerfont treatment by baseline disease control status (Study 202). Participants were required to be on a stable regimen of glucocorticoid replacement for a minimum of 30 days before baseline that was expected to remain stable throughout the study. Assessments were taken at approximately 8 am prior to morning glucocorticoid dose. Geometric means are presented with percentage reduction derived from the geometric mean ratios. Axes are different between poor and good disease control to enable presentation of good disease control participants with mean values below the target levels. Abbreviation: QD, once daily.CC BY-NC-ND · PubMed Central
Figure 6. Changes in testicular adrenal rest tumor (TART) measurements in 1 participant in Study 201. Pretreatment and post 6-week tildacerfont treatment testicular ultrasounds of single TART in a participant. Treatment with tildacerfont reduced the TART approximately 23% in volume.
Figure 6. Changes in testicular adrenal rest tumor (TART) measurements in 1 participant in Study 201. Pretreatment and post 6-week tildacerfont treatment testicular ultrasounds of single TART in a participant. Treatment with tildacerfont reduced the TART approximately 23% in volume.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 46

Metadata

Authors
Sarafoglou, K., Barnes, C. N., Huang, M., Imel, E. A., Madu, I.-J., Merke, D. P., Moriarty, D., Nakhle, S., Newfield, R. S., Vogiatzi, M. G., & Auchus, R. J.
Affiliations
  • University of Minnesota (US)
  • Seton Medical Center (US)
  • Indiana University Indianapolis (US)
  • Diabetes Associates Medical Group, Orange, CA, USA
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
  • Palm Medical Group, Las Vegas, NV, USA
  • University of California San Diego (US)
  • Children's Hospital of Philadelphia (US)
  • University of Michigan (US)
Corresponding author
Barnes, Chris N
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2021-06-19
Volume
106
Issue
11
Pages
e4666-e4679
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3169341211
Cited by
46
References
25
Citations by year
2026: 11 · 2025: 7 · 2024: 10 · 2023: 9 · 2022: 7 · 2021: 2
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
  • Spruce Biosciences, Inc.
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
classic congenital adrenal hyperplasia, 21-hydroxylase deficiency, CRF1 receptor antagonist, glucocorticoid dose reduction, androstenedione, ACTH, 17-hydroxyprogesterone, hyperandrogenism, adult patients, drug safety and efficacy, adverse events, headache, upper respiratory tract infection
MeSH terms
CRF Receptor, Type 1, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Aged, Androstenedione, Female, Follow-Up Studies, Humans, Male, Middle Aged, Biomarkers, Receptors, Corticotropin-Releasing Hormone, 17-alpha-Hydroxyprogesterone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. https://app.cochat.ai/papers/10.1210/clinem/dgab438
The paper
Sarafoglou, K., Barnes, C. N., Huang, M., Imel, E. A., Madu, I.-J., Merke, D. P., Moriarty, D., Nakhle, S., Newfield, R. S., Vogiatzi, M. G., & Auchus, R. J. (2021). Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab438

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.